August 29, 2021
2 mins read

ICMR releases new study on Covaxin doses

The antibody responses of individuals with confirmed pre-vaccination SARS-CoV-2 infection were compared with those individuals without prior evidence of infection…reports Asian Lite News.

A single-dose of Covaxin provides a similar immunity response in previously Covid-infected people as those without previous history of Covid infection with two doses of vaccine, says Indian Council of Medical Research’s latest study.

The ICMR in its recent study has found that the people already infected with Covid-19 while taking a dose of Covaxin have the same or increased antibody response as unaffected people taking two doses of Covaxin.

The pilot study was undertaken to examine SARS-CoV-2 specific antibody responses after day 0 (baseline before vaccination), day 28A2 days post-first dose (month 1) and day 56A2 days post-first dose (month 2) of BBV152 in a group of healthcare professionals as well as frontline workers.

The antibody responses of individuals with confirmed pre-vaccination SARS-CoV-2 infection were compared with those individuals without prior evidence of infection.

The blood specimens were collected from healthcare professionals and frontline workers who received BBV152 vaccine at vaccination centres in Chennai, India, during February to May 2021.

Blood samples were collected before receiving the first dose of BBV152. Prior infection with SARS-CoV-2 was determined by SARS-CoV-2 IgG positivity at baseline. The study was approved by the Ethics Committee of ICMR-NIRT.

Antibody levels were measured at three time points: on the day of vaccination (baseline), at month one following the first dose and at month two following the first dose.

https://www.youtube.com/watch?v=ngCvDWwuEgM

The results were determined via a calibration curve, which is an instrument specifically generated by two-point calibration and a master curve provided via the reagent QR code.

Almost all participants with prior Covid-19 infection except two had detectable antibodies at the time of vaccination. This study offers evidence in support of public health-oriented and immunologically sustained vaccine strategies.

Lokesh Sharma, Scientist and Media Coordinator, ICMR, says, “This is a pilot study. If such findings are confirmed in large population studies, a single dose of BBV152 vaccine may be recommended to previously confirmed Covid patients so that the naA-ve individuals could attain the larger benefit of a limited vaccine supply.”

ALSO READ-ICMR issues guidance on COVID 19 death cases

READ MORE-No compromise on Covaxin quality, says Bharat Biotech

Previous Story

Indigenously built ‘Vigraha’ commissioned into Coast Guard

Next Story

India administers record 10 million vax doses in a day

Latest from -Top News

Modi, Cyprus President Hold Talks

Both leaders explored avenues to deepen cooperation in trade, investment, security, and technology…reports Asian Lite News Prime Minister Narendra Modi on Monday held wide-ranging discussions with Cyprus President Nikos Christodoulides at the

Jaishankar Dials UAE, Armenia as Mideast Heats Up

EAM Jaishankar discussed the fast-evolving situation and emphasised the importance of dialogue and cooperation….reports Asian Lite News External Affairs Minister S. Jaishankar held telephonic conversations with his counterparts in the United Arab

G7 Summit Eyes Energy Security

Monday’s schedule includes a 90-minute session among G7 leaders to discuss the global economic outlook…reports Asian Lite News The Group of Seven (G7) summit unveiled its slimmed-down agenda, prioritising discussions on the

Modi Mania Grips Canada

This is PM Modi’s first visit to Canada after a year marked by diplomatic tensions…reports Asian Lite News As Prime Minister Narendra Modi gears up for his visit to Canada for the

Modi’s 3-Nation Mission Begins

This three-nation tour is also an opportunity to thank partner countries for their steadfast support to India in our fight against cross-border terrorism…reports Asian Lite News Ahead of his departure for a
Go toTop